Hinge Health Surpasses Q4 Earnings Expectations, Stock Jumps 15%
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1d ago
0mins
Should l Buy HNGE?
Source: NASDAQ.COM
- Earnings Beat: Hinge Health reported Q4 earnings of $0.49 per share, exceeding analysts' expectations of $0.43, with sales reaching $170.7 million, surpassing the forecast of $156.8 million, indicating robust performance in the healthcare platform sector.
- Significant Sales Growth: The company experienced a 46% year-over-year sales increase, with gross margins expanding by 200 basis points, demonstrating substantial market expansion and improved profitability in treating musculoskeletal conditions.
- Strong Free Cash Flow: Hinge's free cash flow increased by 65% to $61.5 million, reflecting effective capital expenditure management and enhancing investor confidence in its financial health.
- Optimistic Future Outlook: The company forecasts a 39% sales growth in Q1 2026, aiming for annual sales of approximately $737 million, with management projecting a 29% growth in non-GAAP earnings, indicating sustained growth potential.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HNGE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HNGE
Wall Street analysts forecast HNGE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HNGE is 64.50 USD with a low forecast of 59.00 USD and a high forecast of 72.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
14 Analyst Rating
14 Buy
0 Hold
0 Sell
Strong Buy
Current: 38.760
Low
59.00
Averages
64.50
High
72.00
Current: 38.760
Low
59.00
Averages
64.50
High
72.00
About HNGE
Hinge Health, Inc. leverages software, including artificial intelligence (AI), to largely automate care for joint and muscle health. The Company has designed its TrueMotion platform to address a spectrum of musculoskeletal (MSK) care from acute injury to chronic pain, to post-surgical rehabilitation. Members receive personalized and automated MSK care through its AI-powered motion tracking technology. It offers electrical nerve stimulation wearable device Enso, all designed and monitored by its AI-supported care team of licensed physical therapists, physicians, and board-certified health coaches. Its platform offers a range of support with multiple programs across many affected areas to provide a continuum of care from prevention to treatment of acute injury and chronic pain, as well as surgery decision support and post-surgical recovery. Enso delivers electrical nerve stimulation designed to provide non-addictive and non-invasive pain relief.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
HINGE HEALTH REPORTS Q4 NON-GAAP DILUTED EARNINGS PER SHARE OF $0.49
- Financial Performance: Hinge Health reported a Q4 non-GAAP diluted net income per share of $0.49.
- Market Position: The company continues to strengthen its position in the digital health sector, focusing on innovative solutions for musculoskeletal care.
See More
HINGE HEALTH INC Reports Q4 Earnings Per Share of USD 0.37
Health Insights: The article discusses recent trends and statistics in health, focusing on various health metrics and their implications for public health.
Economic Impact: It highlights the economic factors influencing health outcomes, including healthcare spending and its correlation with health improvements.
Policy Recommendations: The piece suggests policy changes aimed at enhancing health services and addressing disparities in healthcare access.
Future Projections: It concludes with predictions about future health trends and the potential challenges that may arise in the healthcare sector.
See More
Hinge Health Surges 15% After Beating Q4 Earnings Expectations
- Earnings Beat: Hinge Health reported Q4 earnings of $0.49 per share, surpassing analyst expectations of $0.43, with sales reaching $170.7 million, exceeding the forecast of $156.8 million, indicating strong market performance and profitability.
- Significant Sales Growth: Q4 sales surged 46% year-over-year, with gross margins expanding by 200 basis points, demonstrating Hinge's substantial progress in treating musculoskeletal conditions and enhancing its competitive position in the market.
- Strong Cash Flow: Free cash flow increased by 65% to $61.5 million, reflecting the company's conservative approach to capital expenditures, allowing investors to rely on accurate cash flow figures and bolstering investor confidence.
- Optimistic Future Outlook: Hinge forecasts a 39% sales growth in Q1 2026, aiming for approximately $737 million in annual sales, with management projecting non-GAAP earnings growth to exceed sales growth, highlighting the company's potential for continued expansion.
See More
Hinge Health Surpasses Q4 Earnings Expectations, Stock Jumps 15%
- Earnings Beat: Hinge Health reported Q4 earnings of $0.49 per share, exceeding analysts' expectations of $0.43, with sales reaching $170.7 million, surpassing the forecast of $156.8 million, indicating robust performance in the healthcare platform sector.
- Significant Sales Growth: The company experienced a 46% year-over-year sales increase, with gross margins expanding by 200 basis points, demonstrating substantial market expansion and improved profitability in treating musculoskeletal conditions.
- Strong Free Cash Flow: Hinge's free cash flow increased by 65% to $61.5 million, reflecting effective capital expenditure management and enhancing investor confidence in its financial health.
- Optimistic Future Outlook: The company forecasts a 39% sales growth in Q1 2026, aiming for annual sales of approximately $737 million, with management projecting a 29% growth in non-GAAP earnings, indicating sustained growth potential.
See More
Hinge Health Reports Strong Q4 Earnings, Exceeds Expectations
- Strong Performance: Hinge Health reported adjusted earnings per share of 49 cents for Q4, surpassing the expected 39 cents, with sales reaching $170.73 million, a 46% year-over-year increase, highlighting the company's robust position in pain management.
- Margin Improvement: The gross margin rose to 84% from 82% a year ago, while the adjusted gross margin reached 85%, indicating ongoing enhancements in cost management and profitability.
- Client and Member Growth: The number of clients increased by 25% year-over-year to 2,830, and membership grew by 47% to 782,890, reflecting significant market penetration and demand for services.
- Positive Outlook: Hinge Health expects Q1 2026 sales between $171 million and $173 million, exceeding the consensus of $160.28 million, demonstrating strong commercial momentum and sustained profitability.
See More
Hinge Health Reports Strong Q4 2025 Earnings with 46% Revenue Growth
- Significant Revenue Growth: Hinge Health reported $171 million in Q4 revenue, a 46% year-over-year increase, with full-year revenue reaching $588 million, reflecting a 51% growth compared to 2024, showcasing strong momentum in the digital health sector.
- Expanded Client Base: By the end of 2025, the company had over 2,800 clients covering nearly 25 million contracted lives, with 53% of clients from the Fortune 100, indicating a significant penetration among large enterprises.
- Effective AI Tools: The rollout of the AI assistant Robin resulted in a 28% reduction in care team time per asynchronous session, while achieving a 92% member satisfaction rating, which not only improved service efficiency but also enhanced customer loyalty.
- Optimistic Future Outlook: The CFO projected Q1 2026 revenue to be between $171 million and $173 million, representing a 39% year-over-year growth, with full-year revenue guidance of $732 million to $742 million, reflecting strong confidence in future growth.
See More
HINGE HEALTH REPORTS Q4 NON-GAAP DILUTED EARNINGS PER SHARE OF $0.49
- Financial Performance: Hinge Health reported a Q4 non-GAAP diluted net income per share of $0.49.
- Market Position: The company continues to strengthen its position in the digital health sector, focusing on innovative solutions for musculoskeletal care.
See More
HINGE HEALTH INC Reports Q4 Earnings Per Share of USD 0.37
Health Insights: The article discusses recent trends and statistics in health, focusing on various health metrics and their implications for public health.
Economic Impact: It highlights the economic factors influencing health outcomes, including healthcare spending and its correlation with health improvements.
Policy Recommendations: The piece suggests policy changes aimed at enhancing health services and addressing disparities in healthcare access.
Future Projections: It concludes with predictions about future health trends and the potential challenges that may arise in the healthcare sector.
See More
Hinge Health Surges 15% After Beating Q4 Earnings Expectations
- Earnings Beat: Hinge Health reported Q4 earnings of $0.49 per share, surpassing analyst expectations of $0.43, with sales reaching $170.7 million, exceeding the forecast of $156.8 million, indicating strong market performance and profitability.
- Significant Sales Growth: Q4 sales surged 46% year-over-year, with gross margins expanding by 200 basis points, demonstrating Hinge's substantial progress in treating musculoskeletal conditions and enhancing its competitive position in the market.
- Strong Cash Flow: Free cash flow increased by 65% to $61.5 million, reflecting the company's conservative approach to capital expenditures, allowing investors to rely on accurate cash flow figures and bolstering investor confidence.
- Optimistic Future Outlook: Hinge forecasts a 39% sales growth in Q1 2026, aiming for approximately $737 million in annual sales, with management projecting non-GAAP earnings growth to exceed sales growth, highlighting the company's potential for continued expansion.
See More
Hinge Health Surpasses Q4 Earnings Expectations, Stock Jumps 15%
- Earnings Beat: Hinge Health reported Q4 earnings of $0.49 per share, exceeding analysts' expectations of $0.43, with sales reaching $170.7 million, surpassing the forecast of $156.8 million, indicating robust performance in the healthcare platform sector.
- Significant Sales Growth: The company experienced a 46% year-over-year sales increase, with gross margins expanding by 200 basis points, demonstrating substantial market expansion and improved profitability in treating musculoskeletal conditions.
- Strong Free Cash Flow: Hinge's free cash flow increased by 65% to $61.5 million, reflecting effective capital expenditure management and enhancing investor confidence in its financial health.
- Optimistic Future Outlook: The company forecasts a 39% sales growth in Q1 2026, aiming for annual sales of approximately $737 million, with management projecting a 29% growth in non-GAAP earnings, indicating sustained growth potential.
See More
Hinge Health Reports Strong Q4 Earnings, Exceeds Expectations
- Strong Performance: Hinge Health reported adjusted earnings per share of 49 cents for Q4, surpassing the expected 39 cents, with sales reaching $170.73 million, a 46% year-over-year increase, highlighting the company's robust position in pain management.
- Margin Improvement: The gross margin rose to 84% from 82% a year ago, while the adjusted gross margin reached 85%, indicating ongoing enhancements in cost management and profitability.
- Client and Member Growth: The number of clients increased by 25% year-over-year to 2,830, and membership grew by 47% to 782,890, reflecting significant market penetration and demand for services.
- Positive Outlook: Hinge Health expects Q1 2026 sales between $171 million and $173 million, exceeding the consensus of $160.28 million, demonstrating strong commercial momentum and sustained profitability.
See More
Hinge Health Reports Strong Q4 2025 Earnings with 46% Revenue Growth
- Significant Revenue Growth: Hinge Health reported $171 million in Q4 revenue, a 46% year-over-year increase, with full-year revenue reaching $588 million, reflecting a 51% growth compared to 2024, showcasing strong momentum in the digital health sector.
- Expanded Client Base: By the end of 2025, the company had over 2,800 clients covering nearly 25 million contracted lives, with 53% of clients from the Fortune 100, indicating a significant penetration among large enterprises.
- Effective AI Tools: The rollout of the AI assistant Robin resulted in a 28% reduction in care team time per asynchronous session, while achieving a 92% member satisfaction rating, which not only improved service efficiency but also enhanced customer loyalty.
- Optimistic Future Outlook: The CFO projected Q1 2026 revenue to be between $171 million and $173 million, representing a 39% year-over-year growth, with full-year revenue guidance of $732 million to $742 million, reflecting strong confidence in future growth.
See More
